Double-Blind, Randomized, Placebo-Controlled Pilot Study of the Safety and Efficacy of Myobloc (Botulinum Toxin Type B) for the Treatment of Palmar Hyperhidrosis

Baumann, Leslie; Slezinger, Anele; Halem, Monica; Vujevich, Justin; Mallin, Karin; Charles, Carlos A.; Martin, Lucy; Black, Laura J.; Bryde, Joy

doi:10.1111/j.1524-4725.2005.31071

Cited by 33 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For 9 (HHIQ [28], OHQL [24], Tolder survey [18], Lamy7 [41], P-HQOL [50], and 4 without name [8, 10, 19, 69]), we were not able to find an article describing the validation of the questionnaire. Three used modified versions of a validated questionnaire [14, 19, 47].…”

Section: Resultsmentioning

confidence: 78%

“…The percentage of improvement of the overall score was reported in 15% (10/67) of the studies [18, 26, 36, 38, 42, 51, 58, 59, 64, 68], and 10 gave unclear or no numerical values [12, 13, 28, 32, 34, 45, 50, 61, 66, 69]. …”

Section: Resultsmentioning

confidence: 99%

“…QOL was a primary judgment criterion in 8 studies [8, 15, 16, 22, 24, 25, 50, 64]. QOL was a secondary endpoint in 88% (59/67) of the analyzed reports.…”

Section: Resultsmentioning

confidence: 99%

“…The remaining 67 articles satisfied our criteria [7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73]. Sixteen concerned atopic dermatitis [7, 13, 14, 18,20,21,22, 26, 29, 31, 42, 46, 56, 66, 67, 70], 1 chronic eczema of the hands [9], 25 psoriasis [10, 17, 27, 30, 33,35,36,37,38,39,...…”

Section: Resultsmentioning

confidence: 99%

“…In 45% (30/67) of the articles, it was not possible to verify comparability for QOL characteristics at inclusion because the mean of the overall score (and/or for each dimension) was not available [7,8,9, 13, 19, 22, 23,26,27,28, 32, 34, 37, 38,42,43,44, 46, 49, 50,53,54,55, 57, 59, 60, 62,70,71,72]. In one, QOL scores were not comparable at inclusion [11].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Poor Reporting of Quality of Life Outcomes in Dermatology Randomized Controlled Clinical Trials

et al. 2007

View full text Add to dashboard Cite

Background: Because many dermatological diseases are chronic but not life-threatening, consideration of their impact on health-related quality of life (QOL) seems essential. Objective: To analyze the use of QOL as an evaluation endpoint in randomized clinical trials concerning skin diseases. Methods: Studies identified by computerized search of 3 bibliographical databases were selected, and their data on QOL as an evaluation endpoint were collected and analyzed. Results: Among the 67 studies retained, 87% did not adequately describe the questionnaires; 75% did not address handling of missing data; 95% did not calculate the number of subjects needed to obtain the desired statistical power; 95% did not disclose before-and-after results as means of overall scores and each dimension. Conclusion: Our analysis highlighted methodological weaknesses in the use of QOL questionnaire and poor reporting of QOL outcomes in randomized clinical trials.

show abstract

Section: Resultsmentioning

confidence: 78%

Section: Resultsmentioning

confidence: 99%

“…QOL was a primary judgment criterion in 8 studies [8, 15, 16, 22, 24, 25, 50, 64]. QOL was a secondary endpoint in 88% (59/67) of the analyzed reports.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Poor Reporting of Quality of Life Outcomes in Dermatology Randomized Controlled Clinical Trials

et al. 2007

View full text Add to dashboard Cite

show abstract

Complications and Diffusion

2017

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2005

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Double-Blind, Randomized, Placebo-Controlled Pilot Study of the Safety and Efficacy of Myobloc (Botulinum Toxin Type B) for the Treatment of Palmar Hyperhidrosis

Cited by 33 publications

References 23 publications

Poor Reporting of Quality of Life Outcomes in Dermatology Randomized Controlled Clinical Trials

Poor Reporting of Quality of Life Outcomes in Dermatology Randomized Controlled Clinical Trials

Complications and Diffusion

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About